Inozyme Pharma (Nasdaq:INZY) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

INZY Stoklara Genel Bakış

INZY temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Inozyme Pharma, Inc. Rakipler

XOMA Royalty

NasdaqGM:XOMA

US$323.5m

MeiraGTx Holdings

NasdaqGS:MGTX

US$321.2m

Aldeyra Therapeutics

NasdaqCM:ALDX

US$317.3m

Instil Bio

NasdaqCM:TIL

US$315.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Inozyme Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$5.17
52 Haftanın En Yüksek Seviyesi	US$7.80
52 Haftanın En Düşük Seviyesi	US$2.69
Beta	1.51
11 Aylık Değişim	3.82%
3 Aylık Değişim	12.39%
1 Yıllık Değişim	33.94%
33 Yıllık Değişim	-49.66%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-70.52%

Son Haberler & Güncellemeler

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Aug 03

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Jul 30

Recent updates

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Jul 19

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Jul 12

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Apr 06

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Dec 22

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Sep 08

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

May 22

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

May 07

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Feb 06

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Jan 04

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Dec 03

Inozyme Pharma EPS misses by $1.02

Nov 12

Hissedar Getirileri

	INZY	US Biotechs	US Pazar
7D	-0.2%	-0.5%	0.4%
1Y	33.9%	18.3%	32.6%

Getiri vs. Endüstri: INZY geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: INZY geçen yıl % 34.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is INZY's price volatile compared to industry and market?
INZY volatility
INZY Average Weekly Movement	8.4%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: INZY son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: INZY 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	59	Doug Treco	www.inozyme.com

Klinik aşamada bir nadir hastalık biyofarmasötik şirketi olan Inozyme Pharma, Inc. vaskülatür, yumuşak doku ve iskelet hastalıklarının tedavisi için yeni terapötikler geliştirmeye odaklanmaktadır. Şirketin öncü ürün adayı, ENPP1 ve ABCC6 eksikliklerinin yanı sıra hemodiyaliz alan son dönem böbrek hastalığı olan hastaların tedavisi için çözünür, rekombinant, genetik olarak tasarlanmış ve füzyon proteini olan INZ-701'dir. Belirtilen terapötik ve profilaktik ürünler için Yale Üniversitesi ile bir lisans anlaşması vardır.

Inozyme Pharma, Inc. Temel Bilgiler Özeti

Inozyme Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
INZY temel i̇stati̇sti̇kler
Piyasa değeri	US$324.34m
Kazançlar(TTM)	-US$88.56m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-3.7x

F/K Oranı

INZY aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
INZY gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$88.56m
Kazançlar	-US$88.56m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.41
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	48.0%

INZY uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

INZY Stoklara Genel Bakış

Ödüller

Risk Analizi

Inozyme Pharma, Inc. Rakipler

NasdaqGM:XOMA

US$323.5m

NasdaqGS:MGTX

US$321.2m

NasdaqCM:ALDX

US$317.3m

NasdaqCM:TIL

US$315.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Financial position

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

New major risk - Revenue and earnings growth

Price target decreased by 7.5% to US$19.43

Recent updates

New major risk - Financial position

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

New major risk - Revenue and earnings growth

Price target decreased by 7.5% to US$19.43

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc., Annual General Meeting, Jun 18, 2024

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency (PXE) and ENPP1 Deficiency

CEO & Chairman exercised options and sold US$52k worth of stock

New minor risk - Share price stability

Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency

New major risk - Revenue and earnings growth

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions

Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

New minor risk - Share price stability

Price target decreased by 9.3% to US$20.50

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Price target increased by 8.5% to US$22.60

Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701

Insufficient new directors

Price target decreased by 13% to US$19.17

Inozyme Pharma, Inc. Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

Price target increased by 8.5% to US$21.80

Inozyme Pharma, Inc. Provides Business Updates

Inozyme Pharma, Inc. Announces First Self-Administration of Inz-701 in Ongoing Enpp1 Deficiency Phase 1/2 Clinical Trial

Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

Price target increased to US$23.20

Inozyme Pharma GAAP EPS of -$0.38

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Index

Inozyme Pharma, Inc. Appoints Kurt Gunter as Chief Medical Officer

Price target decreased to US$29.40

Inozyme Pharma, Inc. Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

Price target decreased to US$30.00

Inozyme Pharma, Inc. Announces Management Changes

High number of new directors

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Price target decreased to US$32.25

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Growth Index

President exercised options and sold US$65k worth of stock

Inozyme Pharma, Inc. Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of Inz-701 in Abcc6 Deficiency

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Senior Vice President of Finance Stephen Basso has left the company

Inozyme Pharma, Inc. Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

Member of Scientific Advisory Board has left the company

Member of Scientific Advisory Board has left the company